Module COAG-04 · Version 1.0
Antiplatelet Drugs and Laboratory Monitoring
A working guide to matching aspirin, P2Y12 inhibitors, GP IIb/IIIa inhibitors, and phosphodiesterase III inhibitors to the platelet pathway each one alters, choosing the test family that actually answers a defined pharmacodynamic question, and recognizing the preanalytical and biological factors that can be mistaken for drug effect.
Your next section
Start section 1Read without an account. Sign in to save.
Who this module is for
Clinical laboratory scientists and trainees who perform or interpret platelet-function testing and coagulation studies.
Learning objectives
- Map aspirin, P2Y12 inhibitors, GP IIb/IIIa inhibitors, and phosphodiesterase III inhibitors to the platelet pathway each drug alters
- Distinguish drug exposure, pharmacodynamic response, adherence questions, and procedural risk questions, and match each to a defensible test family
- Recognize preanalytical and biological factors, including thrombocytopenia, anemia, inflammation, and specimen timing, that can mimic poor or excessive drug effect
How completion works
Mark every required section done and answer every knowledge check in those sections correctly. The final save completes the module automatically.
Sources
14 sources
1. Centers for Medicare & Medicaid Services. 42 CFR Section 493.1253, Establishment and verification of performance specifications. Federal regulation.
Source note · federal regulation
2. Centers for Medicare & Medicaid Services. 42 CFR Section 493.1256, Control procedures. Federal regulation.
Source note · federal regulation
3. College of American Pathologists. Test Method Validation and Verification, checklist-requirements teaching document. Accreditation standard.
Source note · accreditation standard
4. Clinical and Laboratory Standards Institute. H58-A: Platelet Function Testing by Aggregometry. 2008, archived catalog record. Consensus standard.
Source note · consensus standard
5. Cattaneo M, Cerletti C, Harrison P, et al. Recommendations for the standardization of light transmission aggregometry: a consensus of the Working Party from the Platelet Physiology Subcommittee of SSC/ISTH. J Thromb Haemost. 2013;11:1183-1189.
Source note · consensus standard
6. U.S. Food and Drug Administration. YOSPRALA (aspirin and omeprazole) prescribing information. Revised 2023.
Source note · manufacturer labeling
7. U.S. Food and Drug Administration. PLAVIX (clopidogrel bisulfate) prescribing information. Revised 2022.
Source note · manufacturer labeling
8. U.S. Food and Drug Administration. INTEGRILIN (eptifibatide) prescribing information. Revised 2021.
Source note · manufacturer labeling
9. U.S. Food and Drug Administration. PLETAL (cilostazol) prescribing information. Revised 2015.
Source note · manufacturer labeling
10. U.S. Food and Drug Administration. 510(k) K051231, VerifyNow P2Y12 Assay. Device clearance summary.
Source note · manufacturer labeling
11. Paniccia R, Priora R, Liotta AA, Abbate R. Platelet function tests: a comparative review. Vasc Health Risk Manag. 2015;11:133-148.
Source note · peer-reviewed literature
12. Lordkipanidze M. Platelet preparation for function testing in the laboratory and clinic: historical and practical aspects. Res Pract Thromb Haemost. 2019;3:615-622.
Source note · peer-reviewed literature
13. Watson SP, et al. Platelet phenotyping and function testing in thrombocytopenia. J Thromb Haemost. 2021;19:31-44.
Source note · peer-reviewed literature
14. Sibbing D, et al. International consensus statement on platelet function and genetic testing in percutaneous coronary intervention: 2024 update. JACC Cardiovasc Interv. 2024;17:2361-2377.
Source note · professional society guidance